European recommendations on organisation of interventional care in acute stroke (EROICAS)
- PMID: 31008277
- PMCID: PMC6301238
- DOI: 10.1177/2396987316659033
European recommendations on organisation of interventional care in acute stroke (EROICAS)
Conflict of interest statement
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Cognard: Consultancies: Medtronic, Sequent, Codman, Microvention, Stryker. No other conflicts of interest reported. Fiehler: Jens Fiehler has received fees as consultant or lecturer from Acandis, Bayer, Boehringer-Ingelheim, Codman, Covidien, MicroVention, Penumbra, Philips, Sequent, Siemens and Stryker. Consultant for Codman, MicroVention. Lectures for Boehringer-Ingelheim, Covidien, and Penumbra. Funding to institution: MicroVention. Unrelated: Consultant for Acandis, Sequent, Stryker. Lectures for Bayer, Philips, Siemens. Funding to Institution: DFG, BMBF, BMWi. Gallitelli: None. Jansen: Olav Jansen was a co-author of SWIFT-Prime, and is a steering committee member of SITS Open. Kobayashi: Employment, consultancies, stock ownership: none. Honoraria: Procardia Medical sp. Z o.o./Microvention, Travel grants: ev3/Covidien/Medtronic, Balt Extrusion. Mazighi: Consultancies: Servier, Boehringer Ingelheim; travel or speaker honoraria: Covidien, Boehringer Ingelheim, Aztra Zeneca and Bayer. Muir: No personal conflicts of interest. Institutional conflicts of interest: Grants to support the PISTE trial from the Stroke Association, National Institute of Health Research Health Technology Assessment programme, and unrestricted grants from Covidien (Medtronic) and Codman, to the University of Glasgow. Intellectual conflict of interest: Co-PI of the PISTE trial. Schaller: None. Schellinger: Employment: none, consultancies: Boehringer Ingelheim, Bayer, Daiichi Sankyo, Pfizer, Cerevast, Photothera, Covidien, stock ownership: none, honoraria Boehringer Ingelheim, Bayer, Daiichi Sankyo, Pfizer, Cerevast, Photothera, Covidien, paid expert testimony: expert witness at German courts, patents or patent applications: none, travel grants: Biogen, Novartis, Genzyme, Boehringer Ingelheim, Bayer, Daiichi Sankyo, Serono.
References
-
- Berkhemer OA, Fransen PSS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015; 372: 11–20. - PubMed
-
- Campbell BC, Mitchell PJ, Kleinig TJ, et al. EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015; 372: 1009–1018. - PubMed
-
- Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015; 372: 1019–1030. - PubMed
-
- Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015; 372: 2296–2306. - PubMed
-
- Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015; 372: 2285–2295. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
